Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas

References

• Alieva M, Bagó JR, Aguilar E, et al. (2012). Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response. PLoS ONE 7:1–11.
   Web of Science ®Google Scholar
• Alyautdin R, Khalin I, Nafeeza MI, et al. (2014). Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine 9:795–811.
   PubMed Web of Science ®Google Scholar
• Amin K, Dannenfelser RM. (2006). In vitro hemolysis: guidance for pharmaceutical scientist. J Pharm Sci Exp Pharmacol 95:1173–6.
   PubMed Web of Science ®Google Scholar
• Bagó JR, Alieva M, Soler C, et al. (2013). Endothelial differentiation of adipose tissue-derived mesenchymal stromal cells in glioma tumors: implications for cell-based therapy. Mol Ther 21:1758–66.
   PubMed Web of Science ®Google Scholar
• Bazile DV. (2014). Nanotechnologies in drug delivery - an industrial perspective. J Drug Deliv Sci Technol 24:12–21.
   Web of Science ®Google Scholar
• Béduneau A, F, Hindré A, Clavreul JC, et al. (2008). Brain targeting using novel lipid nanovectors. J Control Release 126:44–9.
   PubMed Web of Science ®Google Scholar
• Bertrand Y, Currie JC, Poirier J, et al. (2011). Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer 105:1697–707.
   PubMed Web of Science ®Google Scholar
• Bickel U. (2005). How to measure drug transport across the blood-brain barrier. Neurotherapeutics 2:15–26.
   Google Scholar
• Boje KMK. (2002). Unit 7.4: in vivo measurement of blood-brain barrier permeability. In: Skolnick P, ed. Current protocols in neurosciences. New York: John Wiley & Sons, 7.19.1–7.19.39.
   Google Scholar
• Borrós GS, Rivero MFX, Cascante CA. (2014). Polypeptides for blood-brain barrier transport. Patent publication number: WO 2014076655 A1.
   Google Scholar
• Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. (2014). Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-Oncology 16:113–22.
   PubMed Web of Science ®Google Scholar
• Chaichana KL, Zadnik P, Weingart JD, et al. (2013). Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118:812–20.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. (2010). Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10:1537–44.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Kormanik P. (1995). Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066–71.
   PubMed Web of Science ®Google Scholar
• Crown J, O’Leary M, Ooi WS. (2004). Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9: 24–32.
   PubMed Web of Science ®Google Scholar
• Demeule M, Currie JC, Bertrand Y, et al. (2008). Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 106: 1534–44.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Clogston JD, Neun BW, et al. (2008). Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett 8:2180–7.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. (2007). Immunological properties of engineered nanomaterials. Nat Nanotechnol 2:469–78.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE, eds. (2013). Handbook of Immunological Properties of Engineered Nanoparticles. 2nd ed. Singapore: World Scientific Publishing.
   Google Scholar
• Duncan R, Gaspar R. (2011). Nanomedicine(s) under the microscope. Mol Pharm 8:2101–41.
   PubMed Web of Science ®Google Scholar
• Fessi H, Puisieux F, Devissaguet JP, et al. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:1–4.
   Web of Science ®Google Scholar
• Fonseca C, Simoes S, Gaspar R. (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83:273–86.
   PubMed Web of Science ®Google Scholar
• Gaudin A, Andrieux K, Couvreur P. (2015). Nanomedicines and stroke: toward translational research. J Drug Deliv Sci Technol 30:278–99.
   Web of Science ®Google Scholar
• Ge, Y, Li, S, Wang, S, Moore, R, Eds. (2014). Nanomedicine. Otawa: Springer.
   Google Scholar
• Glantz MJ, Choy H, Kearns CM, et al. (1995). Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87: 1077–81.
   PubMed Web of Science ®Google Scholar
• Gref R, Domb A, Quellec P, et al. (1995). The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 16:215–33.
   PubMed Web of Science ®Google Scholar
• Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. (2007). Characterization of nanoparticles for therapeutics. Nanomedicine 2:789–803.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Gendelman HE. (2007). Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci (Oxford) 32:1054–82.
   PubMed Web of Science ®Google Scholar
• Kanzawa T, Germano IM, Komata T, et al. (2004). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448–57.
   PubMed Web of Science ®Google Scholar
• Kanzawa T, Germano IM, Kondo Y, et al. (2003). Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 89:922–9.
   PubMed Web of Science ®Google Scholar
• Kim JA, Casalini T, Brambilla D, Leroux JC. (2016). Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency. Sci Rep 6:34297.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2014). Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev 71: 2–14.
   PubMed Web of Science ®Google Scholar
• Letchford K, Burt H. (2007). A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 65:259–69.
   PubMed Web of Science ®Google Scholar
• Lv S, Li M, Tang Z, et al. (2013). Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta Biomater 9:9330–42.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Mukherjee D, Chaichana KL, et al. (2009a). Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65:463–9.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD, et al. (2009b). Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110:583–8.
   PubMed Web of Science ®Google Scholar
• McGrogan BT, Gilmartin B, Carney DN, McCann A. (2008). Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785:96–132.
   PubMed Web of Science ®Google Scholar
• McNeil SE. (2011). Characterization of nanoparticles intended for drug delivery. New York: Springer.
   Google Scholar
• Miele E, Gian Paolo S, Ermanno M, et al. (2009). Albumin-bound formulation of paclitaxel (AbraxaneABI-007) in the treatment of breast cancer. Int J Nanomedicine 4:99–105.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Anderson DG, , et al. (2015). Accelerating the translation of nanomaterials in biomedicine. ACS Nano 9:6644–54.
   PubMed Web of Science ®Google Scholar
• Mura S, Couvreur P. (2012). Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 64: 1394–416.
   PubMed Web of Science ®Google Scholar
• Neha B, Ganesh B, Preet K. (2013). Drug delivery to the brain using polymeric nanoparticles: a review. Int J Pharma Life Sci 2:107–32.
   Google Scholar
• Nicolas J, Mura S, Brambilla D, et al. (2013). Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev 42:1147–235.
   PubMed Web of Science ®Google Scholar
• Oller-Salvia B, Sánchez-Navarro M, Giralt E, Teixidó M. (2016). Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem Soc Rev 45:4690–707.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Liao P, et al. (2014). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 16:iv1–iv63.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. (2012). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 64 : 61–71.
   Web of Science ®Google Scholar
• Pardridge WM. (2012). Drug transport across the blood–brain barrier. J Cereb Blood Flow Metab 32:1959–72.
   PubMed Web of Science ®Google Scholar
• Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. (2006). Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2: 8–21.
   PubMed Web of Science ®Google Scholar
• Régina A, Demeule M, Ché C, et al. (2009). Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector angiopep-2. Br J Pharmacol 155:185–97.
   Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncolo 10: 459–66.
   PubMed Web of Science ®Google Scholar
• Tosi G, Bortot B. (2013). Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. CurrMed Chem 20:2212–25.
   PubMed Web of Science ®Google Scholar
• Toti US, Guru BR, Grill AE, Panyam J. (2010). Interfacial activity assisted surface functionalization: a novel approach to incorporate maleimide functional groups and cRGD peptide on polymeric nanoparticles for targeted drug delivery. Mol Pharmaceutics 7: 1108–17.
   PubMed Web of Science ®Google Scholar
• Vauthier C, Bouchemal K. (2009). Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 26:1025–58.
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Szoka FC. (2013). Cancer nanomedicines: so many papers and so few drugs!. Adv Drug Deliv Rev 65:80–8.
   PubMed Web of Science ®Google Scholar
• Venkatraman S. (2014). Has nanomedicine lived up to its promise? Nanotechnology 25: 372501.
   PubMed Web of Science ®Google Scholar
• Xiao K, Li Y, Luo J, et al. (2011). The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32:3435–46.
   PubMed Web of Science ®Google Scholar
• Zhang X. (2011). Glioblastoma multiforme: molecular characterization and current treatment strategy (Review). Exp Ther Med 3:9–14.
   PubMed Web of Science ®Google Scholar
• Zhang M, Herion TW, Timke C, et al. (2011). Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia 13:537–49.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wu Y, He B, et al. (2014). Biodegradable polymeric nanoparticles based on amphiphilic principle: construction and application in drug delivery. Sci China Chem 57:461–75.
   Web of Science ®Google Scholar
• Zhu Z. (2013). Effects of amphiphilic diblock copolymer on drug nanoparticle formation and stability. Biomaterials 34: 10238–48.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178–201.
   PubMed Web of Science ®Google Scholar